A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled
(Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two
doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic
Obstructive Pulmonary Disease (COPD) and chronic bronchitis.
